Becton, Dickinson and Company (BDX) Expected to Announce Earnings on Thursday

Becton, Dickinson and Company (NYSE:BDX) is projected to post its Q3 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect the company to announce earnings of $3.44 per share and revenue of $5.50 billion for the quarter.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.07. The business had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The company’s revenue was up 4.5% on a year-over-year basis. During the same period last year, the business earned $3.17 EPS. On average, analysts expect Becton, Dickinson and Company to post $14 EPS for the current fiscal year and $16 EPS for the next fiscal year.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $181.66 on Thursday. The stock has a 50 day moving average price of $174.71 and a 200 day moving average price of $201.68. The company has a quick ratio of 0.64, a current ratio of 1.13 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $52.07 billion, a price-to-earnings ratio of 34.67, a price-to-earnings-growth ratio of 1.38 and a beta of 0.25. Becton, Dickinson and Company has a 52-week low of $163.33 and a 52-week high of $251.99.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be given a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.29%. The ex-dividend date of this dividend is Monday, September 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 79.39%.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. The trade was a 19.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Shan sold 1,166 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by corporate insiders.

Institutional Trading of Becton, Dickinson and Company

A hedge fund recently raised its stake in Becton, Dickinson and Company stock. Brighton Jones LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 98.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,770 shares of the medical instruments supplier’s stock after buying an additional 877 shares during the period. Brighton Jones LLC’s holdings in Becton, Dickinson and Company were worth $401,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Morgan Stanley cut their price target on shares of Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Citigroup lowered Becton, Dickinson and Company from a “strong-buy” rating to a “hold” rating and dropped their price objective for the stock from $217.00 to $185.00 in a report on Thursday, May 22nd. Wells Fargo & Company lowered shares of Becton, Dickinson and Company from an “overweight” rating to an “equal weight” rating in a research report on Thursday, May 1st. Barclays cut their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an “overweight” rating for the company in a report on Tuesday, June 3rd. Finally, The Goldman Sachs Group downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 price objective on the stock. in a report on Friday, May 2nd. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $219.22.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.